Navigation Links
Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
Date:5/15/2013

LOS ANGELES, May 15, 2013 /PRNewswire/ -- On May 8, 2013, Dr. Rongxiang Xu , the founder of "human body regenerative restoration science" and a renowned life and medical scientist who is believed to be the only person who has patented the technology for direct regeneration of damaged organs has filed a lawsuit against Dr. Shinya Yamanaka , one of the winners of the 2012 Nobel Prize in Physiology or Medicine in the Superior Court of California, County of San Francisco. The lawsuit filed alleges, among other things, deception by Dr. Shinya Yamanaka .

(Photo: http://photos.prnewswire.com/prnh/20130515/LA14340)

According to Dr. Xu's attorney, a previous lawsuit was filed by Dr. Xu against the Nobel Assembly on December 3, 2012, urging the Assembly to clarify certain statements made in conjunction with awarding the 2012 Nobel Prize in Physiology or Medicine. Unfortunately, no response clarifying the truth about the science has been received as the case is still pending. Therefore, Dr. Xu has filed another lawsuit directly against Dr. Yamanaka, for alleged deceptive practices employed by Dr. Yamanaka.

Dr. Xu's attorney stated that Dr. Yamanaka's published statements labeling his artificially transgenic cell study as "induction of somatic cells into stem cells", which was the patented technology of Dr. Xu, has caused substantial damages to his reputation and company. Dr. Xu claims that Dr. Yamanaka has deceived a number of well-intentioned professionals into exploration and research on the life science forefront. However, Dr. Xu believes that Dr. Yamanaka has steered these professionals down the wrong path. For example, Dr. Xu believes that even the US government was misled into Dr. Yamanaka's hype when the 2008 state of the union address mentioned favoring a way to reprogram adult skin cells to act like embryonic stem cells, as claimed by Dr. Yamanaka. Dr. Xu believes hundreds of millions in taxpayers' money has been wasted in funding such false science.

The Nobel Assembly granted Dr. Yamanaka the Prize in Physiology or Medicine in 2012, acclaiming his artificially transgenic cells created human regenerative potential. Considering the foreseeable consequences threatening human lives, Dr. Xu is working to stop such deception through the legal process.

Dr. Yamanaka labeled his artificial cell produced by oncogene transferring as "somatic cell induction into pluripotent stem cells", i.e. he claimed his artificially transgenic cell study in the name of the plaintiff's patented technology and called it iPSC in short, which was quickly endorsed and followed by a group of prestigious scientists expecting to solve the ethic issue of embryonic stem cell study.

This term used by Dr. Yamanaka is the core of Dr. Xu's patents, including US Patent 6991813 and Dr. Xu alleges that Dr. Yamanaka's study actually has nothing to do with stem cell. Dr. Yamanaka admitted in his article published in Cell Stem Cell magazine in 2012 that he didn't obtain natural pluripotent stem cells by somatic cell induction. According to Dr. Xu, it is critical to ask why such a ridiculous scientific scam has been prevailing worldwide for the past few years.

Human somatic cell induction into pluripotent stem cell is the core content of the Dr. Xu's patented scientific route of "regeneration of damaged organs" and has been accomplished in clinical application. However, this technology that allows "regeneration of damaged organs" has been hindered from benefiting the general public due to the scientific scam by Dr. Yamanaka, depriving the chances of tens of thousands of patients for getting access to innovative science and technology for cures.

The scientific route of "developing drugs to regenerate damaged organs" has been labeled one of the nation's main topics of focus, and was also discussed by president Obama in his 2013 State of the Union Address, where he stated "Now, if we want to make the best products, we also have to invest in the best ideas. Every dollar we invested to map the human genome returned $140 to our economy. Every dollar. Today, our scientists are mapping the human brain to unlock the answers to Alzheimer's. We're developing drugs to regenerate damaged organs, devising new materials to make batteries 10 times more powerful. Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race. We need to make those investments."

Dr. Xu is thankful for the Obama administration's acknowledgement of this vital area of organ regeneration, and feels that this direction is a blessing for Americans and people worldwide.

Please contact Jane Westgate 336.608.4439 or Cheryl Riley 703.683.1798. The Plaintiff is represented by the Ardent Law Group in California.


'/>"/>
SOURCE Mebo International; Ardent Law Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
2. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
3. Enbrel® (etanercept) Patent Issued
4. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
5. Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
6. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
7. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
8. Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of ... trends in analytical testing are being attributed to new regulatory requirements for all ...
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):